Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company specializing in the research and development of therapies targeting neurological, oncological, and inflammatory diseases. Founded in 2000 and headquartered in Taipei, Taiwan, the company is recognized for its innovation in addressing unmet medical needs within the health technology sector, particularly in major pharmaceuticals. Lumosa Therapeutics develops both proprietary and in-licensed drug candidates, with flagship products such as Naldebain—a post-surgical analgesic injection—already on the market, and others like LT3001 (acute ischemic stroke), LT5001 (uremic pruritus), and LT6001 (neurological disorders) at various clinical or preclinical stages. Operating on a global scale, the company serves markets across Taiwan, Asia, America, and Europe, and engages in additional activities such as investment, consulting, and technical transfer. With a modest employee base, Lumosa Therapeutics plays a strategic role in advancing novel pharmaceuticals, contributing to the biotechnology and medical research industries through its commitment to drug development and clinical innovation.